FIGURE 3.

Difference versus placebo with dapagliflozin 5 and 10 mg for A, change from baseline in HbA1c at week 24 and 52, B, % change from baseline in body weight at week 24 and 52, C, % change from baseline in total daily insulin dose at week 24 in subgroups of patients receiving insulin either via continuous subcutaneous insulin infusion (CSII) or multiple daily injections (MDI). The mixed model included terms for baseline, treatment, study, week, stratum, week*treatment, week*baseline, subgroup, treatment*subgroup, week*subgroup and treatment*week*subgroup. Stratum includes one term for each combination of the three stratification factors on baseline HbA1c, use of personal continuous glucose monitoring system and methods of insulin administration. CI, confidence interval; DAPA, dapagliflozin; PBO, placebo; TDID, total daily insulin dose